148858-04-2

Basic information

• Product Name: 4-<(tert-butoxy)carbonyl>-1,2,3,4-tetrahydroquinoxalin-2-one
• Synonyms: 4-<(tert-butoxy)carbonyl>-1,2,3,4-tetrahydroquinoxalin-2-one
• CAS NO: 148858-04-2
• Molecular Weight: 248.282
• Mol File: 148858-04-2.mol

Chemical Properties

• CAS DataBase Reference: 4-<(tert-butoxy)carbonyl>-1,2,3,4-tetrahydroquinoxalin-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-<(tert-butoxy)carbonyl>-1,2,3,4-tetrahydroquinoxalin-2-one(148858-04-2)
• EPA Substance Registry System: 4-<(tert-butoxy)carbonyl>-1,2,3,4-tetrahydroquinoxalin-2-one(148858-04-2)

Safety Data

• Hazardous Substances Data: 148858-04-2(Hazardous Substances Data)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 59564-59-9 1,2,3,4-tetrahydroquinoxalin-2-one 
• 5428-05-7 n-(2-nitrophenyl)glycine ethyl ester 
• 95-54-5 1,2-diamino-benzene 
• 1493-27-2 ortho-nitrofluorobenzene 

Relevant articles and documents

TETRAHYDROQUINOLINE SUBSTITUTED HYDROXAMIC ACIDS AS SELECTIVE HISTONE DEACETYLASE 6 INHIBITORS

Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a neurological disease, tr

NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS

The present invention relates to novel M1 agonistic compounds of formula (I) and their use in the treatment of cognitive impairment associated i.a. with schizophrenia and in the treatment of other diseases mediated by the muscarinic M1 receptor.

Imidazo[1,5-A]quinoxalines

An invention relating to Imidazo[1,5-a]quinoxalines (I) STR1 which do not contain an endocyclic carbonyl group and which are useful as anxiolytic and sedative/hypnotic agents.

Antagonist, Partial Agonist, and Full Agonist Imidazoquinoxaline Amides and Carbamates Acting through the GABAA/benzodiazepine Receptor

(4RS)-1-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-12,12a-dihydroimidazopyrroloquinoxalin-10(11H)-one (1a), 5-benzoyl-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydroimidazoquinoxaline (13b), and tert-butyl (4S)-12,12a-dihydroimidazopyrroloquinoxaline-1-carboxylate (1e), as well as other imidazoquinoxaline amides and carbamates, represent a new series of compounds which bind with high affinity to the GABAA/benzodiazepine receptor.These compound exhibit a wide range of intrinsic efficacies as measured by TBPS binding ratios.The synthesis of 1a begins with the addition of DL-glutamic acid to 1-fluoro-2-nitrobenzene, followed by reduction of the nitro group and subsequent ring closure to form 3-(carbethoxymethyl)-1,2,3,4-tetrahydroquinoxalin-2-one, followed by a second ring closure to afford (4RS)-1,5-dioxo-1,2,3,4,5,6-hexahydropyrroloquinoxaline as the key intermediate.Appendage of a substituted imidazo ring via the anion of 5-cyclopropyl-1,2,4-oxadiazol-3-yl gives 1a.The (-) and (+)-isomers of 1a were prepared from 1-fluoro-2-nitrobenzene and L- and D-glutamic acid, respectively. 1a and its enantiomers demonstrated affinity for flunitrazepam binding site with Ki's of 0.87, 0.62, and 0.65 nM, respectively.